Chest. 2022 Jan 28:S0012-3692(22)00196-9. doi: 10.1016/j.chest.2022.01.033. Online ahead of print.
ABSTRACT
Direct Oral Anticoagulants (DOACs) are increasingly used in clinical practice and have become essential in the management of atrial fibrillation and venous thromboembolism. The enthusiasm for DOACs has fueled the off-label application of these agents in cardio-pulmonary disease; and their use has often outpaced the evidence supporting their application. This manuscript reviews the evidence and current off-label use of DOACs in various cardio-pulmonary disease states.
PMID:35101404 | DOI:10.1016/j.chest.2022.01.033